Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000000096 | SCV000793037 | likely pathogenic | Lysosomal acid lipase deficiency | 2017-08-08 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000000095 | SCV000931711 | pathogenic | Wolman disease | 2023-07-03 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LIPA protein function. This missense change has been observed in individual(s) with cholesterol ester storage disease (CESD) or Wolman disease (PMID: 8146180, 8598644, 8617513, 23430518). It has also been observed to segregate with disease in related individuals. This variant is also known as L179P. ClinVar contains an entry for this variant (Variation ID: 77). Experimental studies have shown that this missense change affects LIPA function (PMID: 7499245, 10562460). For these reasons, this variant has been classified as Pathogenic. This variant is present in population databases (rs121965086, gnomAD 0.003%). This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 200 of the LIPA protein (p.Leu200Pro). |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000000095 | SCV003844837 | pathogenic | Wolman disease | 2023-02-16 | criteria provided, single submitter | clinical testing | Variant summary: LIPA c.599T>C (p.Leu200Pro) results in a non-conservative amino acid change located in the Alpha/beta hydrolase fold-1 domain (IPR000073) of the encoded protein sequence. This variant is also known as L179P. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251462 control chromosomes (gnomAD). c.599T>C has been reported in the literature in individuals affected with Lysosomal Acid Lipase Deficiency (examples: Pullinger_2015, Ambler_2012, Anderson_1994, Maslen_1995). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (example: Vinje_2019) . Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
OMIM | RCV000000095 | SCV000020238 | pathogenic | Wolman disease | 1995-01-01 | no assertion criteria provided | literature only | |
OMIM | RCV000000096 | SCV000020239 | pathogenic | Lysosomal acid lipase deficiency | 1995-01-01 | no assertion criteria provided | literature only | |
Natera, |
RCV000000096 | SCV002091377 | pathogenic | Lysosomal acid lipase deficiency | 2020-07-07 | no assertion criteria provided | clinical testing |